Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fesoterodine in men post-prostatectomy
NCT01661166Phase 4Completed
- Sponsor
- Abramson Cancer Center
- Start
- Jan 2012
- Primary completion
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) comparing Fesoterodine 4mg with Placebo (2 arms). Primary endpoints: Number of Adverse Events at 3 months and Incidence of Overactive Bladder/Detrusor Overactivity at 3 months. Started Jan 2012; status: completed.
02
Drugs
fesoterodine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT01661166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661166.